Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers, such as PD-L1 expression or tumor mutational burden, often fail…
Plasma proteomics study unlocks predictive biomarkers for TNBC immunotherapy
